CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞的使用是一项重大的治疗进展,改善了多种血液系统恶性肿瘤患者的预后。然而,该疗法有时也会带来危及生命的并发症。因此,了解这些并发症的治疗与管理,尤其是在治疗中心和重症监护室中,具有极其重要的意义。本综述为治疗CAR-T 细胞相关并发症的医生和重症监护医师提供了关于CAR-T 细胞相关并发症(如细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、血液毒性、低丙种球蛋白血症以及CAR-T 细胞诱导的假性进展等)的诊断、管理和治疗建议。
The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies.
However, this therapy has also sometimes life-threatening, complications.
Therefore, knowledge of the treatment and management of these complications, especially in treatment centers and intensive care units, respectively, is of outstanding importance.
This review provides recommendations for the diagnosis, management, and treatment of CAR-T cell-associated complications such as cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, hematotoxicity, hypogammaglobulinemia, and CAR-T cell-induced pseudo-progression amongst others for physicians treating patients with CAR-T cell-associated complications and intensivists.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。